Advanced search
Publication Cover
Journal of Community Hospital Internal Medicine Perspectives Volume 8, 2018 - Issue 2
Journal homepage
955
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity

Adnan Asif Parvez GhiasDepartment of Internal Medicine, St. Elizabeth Health Center, Youngstown, OH, USA;Department of Internal Medicine, Northeastern Ohio Medical University, Rootstown, OH, USACorrespondence[email protected]
,
Shahzeem BhayaniDepartment of Internal Medicine, St. Elizabeth Health Center, Youngstown, OH, USA;Department of Internal Medicine, Northeastern Ohio Medical University, Rootstown, OH, USA
,
David J. GemmelDepartment of Research, St. Elizabeth Health Center, Youngstown, OH, USAORCID Iconhttp://orcid.org/0000-0002-1681-4661
ORCID Icon &
Sudershan K. GargHematology and Oncology, Mercy Health, Youngstown, OH, USA
Pages 87-91 | Received 10 Nov 2017, Accepted 16 Mar 2018, Published online: 17 Apr 2018

References

  • Rammohan A, Sathyanesan J, Rajendran K, et al. A gist of gastrointestinal stromal tumors: a review. World J Gastrointest Oncol. 2013;5(6):102–112.
  • Rutkowski P, Przybył J, Zdzienicki M. Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors. Mol Diagn Ther. 2013;17(1):9–19.
  • Blay JY, von Mehren M, Blackstein ME. Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer. 2010;116(22):5126–5137.
  • Mughal TI, Schrieber A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics. 2010;4:315–323.
  • Kim KW, Shinagare AB, Krajewski KM, et al. Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for management. Korean J Radiol. 2015;16(2):304–313.
  • Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer. 2010;116:184–192.
  • Ran HH, Zhang R, Lu XC, et al. Imatinib-induced decompensated heart failure in an elderly patient with chronic myeloid leukemia: case report and literature review. J Geriatr Cardiol. 2012;9(4):411–414.
  • Jain VV, Pawade H, Gupta OP. Cardiac failure following imatinib treatment–a rare but fatal complication. J Indian Acad Clin Med. 2011;12(3):243–245.
  • Kerkelä R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006;12(8):908–916.
  • Atallah E, Durand JB, Kantarjian H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007;110(4):1233–1237.
  • Fernandez A, Sanguino A, Peng Z, et al. An anti-cancer C-kit kinase inhibitor is re-engineered to make it more active and less cardiotoxic. J Clin Invest. 2007;117(12):4044–4054.
  • Chambers TP, Santiesteban L, Gomez D, et al. Sab mediates mitochondrial dysfunction involved in imatinib mesylate-induced cardiotoxicity. Toxicology. 2017;382:24–35.
  • Perik PJ, Rikhof B, de Jong FA, et al. Results of plasma N terminal pro B-type natriurectic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol. 2008;19:359–361.
  • Ami EB, Demetri GD. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. Expert Opin Drug Saf. 2016;15(4):571–578.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.